The superior therapeutic properties of the rich entire plant CBD cannabis extract compared to single molecule cannabidiol (CBD) have been documented in a revolutionary Israel study.
The article, published in the Pharmacology & Pharmacy newspaper (February 2015), directly challenges one of the sacred cows of Big Pharma and its medical – industrial complex: the idea that”raw” biological science preparations square measure in and of itself of quality and fewer effective than pure single molecule compounds.
The article entitled ‘ Overcoming the bell-shaped response of cannabidiol with cannabis enhanced extract ‘ is even more remarkable in that its co-author, Lumir Hanus, contributed to the discovery of glutamate, the endogenous cannabinoid that was first identified in the mammalian brain in 1992.
Hanus and two Israeli peers from the Hebrew University of Jerusalem reviewed the scientific literature and stated that the anti-inflammatory effects of the pure molecule have been devoted to many preclinical studies over the past 15 years. CBD in various disease animal models, including rheumatoid arthritis, inflammatory intestinal disease, multiple sclerosis, and diabetes. (See CBD preclinical data.)
These analyses have shown that a dose-response curve in the shape of a bell is the administration of pure molecules of unique molecules CBD, meaning that when the amount of CBD surpassed a certain argument, its therapeutic impact has decreased significantly. “Healing was only observed when CBD was given in a very restricted dose range, whereas at lower or higher doses no positive effect was acquired,” the authors detected. CBD-Presented as a reaction to a bell-shaped dose-this unique molecule feature poses serious barriers that limit its effectiveness in a clinical context.
These studies showed that: When the amount of CBD exceeded a certain point, its therapeutic impact was significantly reduced.
The Israeli team tried to determine if the administration of a whole plant CBD would also generate a bell-shaped dose-response curve when given to mice. Or could the extraction of cannabidiol from CBD cannabis be avoided-rich? “The purpose of this study,” the authors reasoned, “was to find a source of CBD that could remove CBD’s dose-response bell-shaped relationship.”
Scientists have been given a CBD “Avidekel”, a variety rich in products from Tikkun Olam, an Israeli medicinal marijuana producer. In this study, known as “clone 202,” Avidekel has almost no THC and is therefore not poisonous. Avidekel’s origins go back to Spain, where farmers developed several “Cannatonic” genotypes (as in “cannabis tonic”), including a strain measuring almost 20 %. CBD with nearly no intoxicating ingredients in dry weight. (Same high-performance CBD-Dominant strain in California is known as “AC DC”)
CBD rich was extracted from clone 202 oil by Israeli researchers. The extract, consisting of 17.9% CBD, 1.1% THC, 1.1% cannabichromene (CBC), 0.2% cannabigerol (CBG) and “traces” of cannabinol (CBN) and cannabivarol (CBDV), was given to mice to assess its anti-inflammatory and pain relieving effect.
Scientists conducted CBD to another group of mice for comparison purposes and assessed their anti-inflammatory and analgesic compounds. They also compared the degree to which a single CBD molecule and entire plant CBD inhibited tumor necrosis factor TNFa), a structural inflammatory signaling molecule. Many diseases, including cancer, Alzheimer’s disease, clinical depression, and irritable bowel syndrome, involved dysregulation of TNFa – alpha production.
The results of previous preclinical research were confirmed by pure CBD tests. Again, the administration generated a single molecule CBD with a narrow therapeutic window, a bell-shaped dose-response curve.
However, a separate pattern of dose-response was observed when mice received the clone extract 202. Rather than showing a bell-shaped curve where only at a certain intensity of CBD a therapeutic effect could be achieved, the entire plant CBD-rich extract caused direct, dose-dependent, pain, inflammation, and TNFa production. “In sharp contrast to the purified CBD,” the Israeli team reported, “Clon extracts provide a clear correlation between anti-inflammatory and antinociceptive responses and doses, and the response increases with increasing doses, making This drug is the ideal solution for clinical use.”
Furthermore, Israeli researchers found that serious pain relief required a small amount of CBD clone extract compared to the much larger amount of CBD required to achieve the same analgesic effect. And while pure and single molecule CBD resulted in a dramatic reduction in efficacy if more than one specific dose was given, the overdose of whole plant CBD The rich extract did not affect its curative power. When more than one efficient clone 202 oil dose was given, its efficacy stabilized, implying a medicinal peak had been reached.
The Israeli study showed that cannabis clone extract 202 “is inferior to CBD for treating inflammatory conditions. Additive or synergistic interactions between CBD and dozens of minor phytocannabinoids and hundreds of non- cannabinoid plant compounds could clarify the greater efficacy of the entire plant extract. “Other components of the extract are probable to be synergistic with CBD to achieve the desired anti-inflammatory intervention that can help to overcome CBD’s bell-shaped dose-response relationship,” the Israeli team implied.
The scientists also thought it was important to look at how cannabis extract from CBD-rich compared to commercial painkillers and anti-inflammatory drugs. They found that there was higher anti-inflammatory power than aspirin in both pure CBD and clone extract 202. In comparison to the powerful inhibitory effect of pure protein, aspirin, but not tramadol, had a slight inhibitory effect on TNFa negligible production CBD and 202 clones.
The main assumption that CBD enhances the dose-response relationship in the presence of other cannabis components is corroborated by recent reports documenting cannabidiol’s anti-proliferation effect on tumor cells and the inhibitory effect of CBD’s sure bladder contractility.
“Many research has been done to isolate and characterize isolated single constituents of traditional herbal remedies in order to find their rationale for therapeutic uses,” concluded the Israeli team. “However, our data, along with those of others, legitimize the introduction of a new generation of phytopharmaceuticals for the treatment of diseases that have been treated with synthetic drugs alone. The therapeutic synergy detected with plant extracts results in the need for a lower amount of active components, resulting in reduced negative effects.